Cargando…

Open field study on the efficacy of fluralaner topical solution for long-term control of flea bite allergy dermatitis in client owned cats in Ile-de-France region

BACKGROUND: Flea bite is considered to be the main cause of allergic dermatitis in cats. There is a need for treatments able to control clinical signs of allergic dermatitis associated with flea bite in cats. This was an open pre-treatment versus post-treatment clinical field study. All cats include...

Descripción completa

Detalles Bibliográficos
Autores principales: Briand, Amaury, Cochet-Faivre, Noelle, Prélaud, Pascal, Armstrong, Rob, Hubinois, Céline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788036/
https://www.ncbi.nlm.nih.gov/pubmed/31604435
http://dx.doi.org/10.1186/s12917-019-2081-8
_version_ 1783458409689907200
author Briand, Amaury
Cochet-Faivre, Noelle
Prélaud, Pascal
Armstrong, Rob
Hubinois, Céline
author_facet Briand, Amaury
Cochet-Faivre, Noelle
Prélaud, Pascal
Armstrong, Rob
Hubinois, Céline
author_sort Briand, Amaury
collection PubMed
description BACKGROUND: Flea bite is considered to be the main cause of allergic dermatitis in cats. There is a need for treatments able to control clinical signs of allergic dermatitis associated with flea bite in cats. This was an open pre-treatment versus post-treatment clinical field study. All cats included in the study presented pruritus, skin lesions or other evidence compatible with flea infestation. Skin lesions were assessed (using SCORFAD) at days 0, 28, 56 and 84 whereas pruritus severity was assessed (using PVAS) at days 0, 15, 28, 56 and 84. On day 0, The fluralaner (280 mg/ml) product (Bravecto® spot-on for cats) was supplied in pipettes containing 0.4, 0.89 and 1.79 ml for cats of 1.2–2.8 kg, > 2.8–6.25 kg and > 6.25–12.5 kg body weight, respectively. The other animals living in the same household also received fluralaner. Based on cytological examination at day 0, oral amoxicillin and clavulanic acid was prescribed for 21 days if indicated. For cats presenting intense pruritus and discomfort at day 0, oral prednisolone at 0.5 mg/kg was prescribed for 3 days. RESULTS: During the study all cats, except for one (cat number 10), improved significantly. Post-treatment median SCORFAD scores at all evaluations were significantly different from the pre-treatment score on day 0 (P values < 0.002 for all three post treatment examination days) with a score reduction of 49% on day 28, 79% on day 56 and 87% on day 84. The PVAS score decreased significantly over the study period for all cats but one (cat number 10). Post-treatment median PVAS scores at all evaluations were significantly different from the pre-treatment PVAS score on day 0 (P value < 0.002 for all four post-treatment days) with a reduction of 46% on day 15, 67% on day 28, 82% on day 56 and 92% on day 84. No adverse reaction or other health issue was reported during the study. CONCLUSIONS: A single topical treatment with fluralaner results in a significant reduction of flea bite allergic dermatitis clinical signs in cats over the subsequent 12 weeks without any additional environmental treatment.
format Online
Article
Text
id pubmed-6788036
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67880362019-10-18 Open field study on the efficacy of fluralaner topical solution for long-term control of flea bite allergy dermatitis in client owned cats in Ile-de-France region Briand, Amaury Cochet-Faivre, Noelle Prélaud, Pascal Armstrong, Rob Hubinois, Céline BMC Vet Res Research Article BACKGROUND: Flea bite is considered to be the main cause of allergic dermatitis in cats. There is a need for treatments able to control clinical signs of allergic dermatitis associated with flea bite in cats. This was an open pre-treatment versus post-treatment clinical field study. All cats included in the study presented pruritus, skin lesions or other evidence compatible with flea infestation. Skin lesions were assessed (using SCORFAD) at days 0, 28, 56 and 84 whereas pruritus severity was assessed (using PVAS) at days 0, 15, 28, 56 and 84. On day 0, The fluralaner (280 mg/ml) product (Bravecto® spot-on for cats) was supplied in pipettes containing 0.4, 0.89 and 1.79 ml for cats of 1.2–2.8 kg, > 2.8–6.25 kg and > 6.25–12.5 kg body weight, respectively. The other animals living in the same household also received fluralaner. Based on cytological examination at day 0, oral amoxicillin and clavulanic acid was prescribed for 21 days if indicated. For cats presenting intense pruritus and discomfort at day 0, oral prednisolone at 0.5 mg/kg was prescribed for 3 days. RESULTS: During the study all cats, except for one (cat number 10), improved significantly. Post-treatment median SCORFAD scores at all evaluations were significantly different from the pre-treatment score on day 0 (P values < 0.002 for all three post treatment examination days) with a score reduction of 49% on day 28, 79% on day 56 and 87% on day 84. The PVAS score decreased significantly over the study period for all cats but one (cat number 10). Post-treatment median PVAS scores at all evaluations were significantly different from the pre-treatment PVAS score on day 0 (P value < 0.002 for all four post-treatment days) with a reduction of 46% on day 15, 67% on day 28, 82% on day 56 and 92% on day 84. No adverse reaction or other health issue was reported during the study. CONCLUSIONS: A single topical treatment with fluralaner results in a significant reduction of flea bite allergic dermatitis clinical signs in cats over the subsequent 12 weeks without any additional environmental treatment. BioMed Central 2019-10-11 /pmc/articles/PMC6788036/ /pubmed/31604435 http://dx.doi.org/10.1186/s12917-019-2081-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Briand, Amaury
Cochet-Faivre, Noelle
Prélaud, Pascal
Armstrong, Rob
Hubinois, Céline
Open field study on the efficacy of fluralaner topical solution for long-term control of flea bite allergy dermatitis in client owned cats in Ile-de-France region
title Open field study on the efficacy of fluralaner topical solution for long-term control of flea bite allergy dermatitis in client owned cats in Ile-de-France region
title_full Open field study on the efficacy of fluralaner topical solution for long-term control of flea bite allergy dermatitis in client owned cats in Ile-de-France region
title_fullStr Open field study on the efficacy of fluralaner topical solution for long-term control of flea bite allergy dermatitis in client owned cats in Ile-de-France region
title_full_unstemmed Open field study on the efficacy of fluralaner topical solution for long-term control of flea bite allergy dermatitis in client owned cats in Ile-de-France region
title_short Open field study on the efficacy of fluralaner topical solution for long-term control of flea bite allergy dermatitis in client owned cats in Ile-de-France region
title_sort open field study on the efficacy of fluralaner topical solution for long-term control of flea bite allergy dermatitis in client owned cats in ile-de-france region
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788036/
https://www.ncbi.nlm.nih.gov/pubmed/31604435
http://dx.doi.org/10.1186/s12917-019-2081-8
work_keys_str_mv AT briandamaury openfieldstudyontheefficacyoffluralanertopicalsolutionforlongtermcontroloffleabiteallergydermatitisinclientownedcatsiniledefranceregion
AT cochetfaivrenoelle openfieldstudyontheefficacyoffluralanertopicalsolutionforlongtermcontroloffleabiteallergydermatitisinclientownedcatsiniledefranceregion
AT prelaudpascal openfieldstudyontheefficacyoffluralanertopicalsolutionforlongtermcontroloffleabiteallergydermatitisinclientownedcatsiniledefranceregion
AT armstrongrob openfieldstudyontheefficacyoffluralanertopicalsolutionforlongtermcontroloffleabiteallergydermatitisinclientownedcatsiniledefranceregion
AT hubinoisceline openfieldstudyontheefficacyoffluralanertopicalsolutionforlongtermcontroloffleabiteallergydermatitisinclientownedcatsiniledefranceregion